Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 7/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.32 |
| ▸ | ADH1C | P00326 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
| ▸ | ADH4 | P08319 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18583670 | 1.00 | SPHK1 (0.37) | SPHK1GNAO1GNAI3GNAI1ADH1C | |
| SCHEMBL19491909 | 1.00 | SPHK1 (0.37) | SPHK1GNAO1GNAI3GNAI1ADH1C | |
| SCHEMBL21940826 | 0.98 | SPHK1 (0.36) | SPHK1GNAO1GNAI3GNAI1ADH1C | |
| SCHEMBL21291133 | 0.95 | SPHK1 (0.33) | SPHK1 | |
| SCHEMBL24368039 | 0.94 | SPHK1 (0.35) | SPHK1GNAO1GNAI3GNAI1 | |
| SCHEMBL20466350 | 0.92 | SPHK1 (0.33) | SPHK1 | |
| SCHEMBL22085914 | 0.88 | SPHK1 (0.31) | SPHK1GNAO1BCHE | |
| SCHEMBL21227093 | 0.83 | SPHK1 (0.33) | SPHK1 | |
| SCHEMBL19251315 | 0.83 | SPHK1 (0.33) | SPHK1 | |
| SCHEMBL19663438 | 0.83 | SPHK1 (0.33) | SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11306095-B2 | Use of pteridinone derivative serving as EGFR inhibitor | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2022-04-19 | — | — | US | disclosed |
| US-20180148454-A1 | USE OF PTERIDINONE DERIVATIVE SERVING AS EGFR INHIBITOR | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11306095-B2 | Use of pteridinone derivative serving as EGFR inhibitor | EGFR, ERBB2, ERBB3 | SPHK1 1664/4885GNAO1 1364/4885GNAI3 590/4885 |
| US-20180148454-A1 | USE OF PTERIDINONE DERIVATIVE SERVING AS EGFR INHIBITOR | EGFR, ERBB2, ERBB3 | SPHK1 1664/4885GNAO1 1364/4885GNAI3 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.